ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2018
Advancing pharmaceuticals and patient safety in Saudi Arabia: A 2030 vision initiative.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Medication Safety Practice in Selected Saudi Hospitals: Alignment with the World Health Organization Global Medication Safety Challenge-An Exploratory Study.Healthcare (Basel, Switzerland) · 2026Article
- Pharmacovigilance in focus: a study on pharmacy students' knowledge, attitudes, and practices in Saudi Arabia.BMC medical education · 2025Article
- Medication Safety in Saudi Arabia: Evaluating the Current Situation and Identifying the Areas for Improvement.Pharmacy (Basel, Switzerland) · 2025Review
- Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop.Frontiers in pharmacology · 2025Article
- Bioequivalence trials for the approval of generic drugs in Saudi Arabia: a descriptive analysis of design aspects.BMC medical research methodology · 2024Article
- Cost-effective track and trace technology for poor-quality chemotherapeutic pharmaceuticals in resource-limited countries: a review of the Chemotherapeutic Paper Analytical Device.Frontiers in medical technology · 2024Review
- A Framework and System Design for Medicines Resources Allocation: A Multi-Stakeholder Assessment of Processes and Electronic Platform Needs.International journal of environmental research and public health · 2023Article
- Healthcare Managers' Perception on Patient Safety Culture.Global journal on quality and safety in healthcare · 2023Article
- Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Review
- Value drivers for pharmaceutical products in health technology assessment (HTA) in Saudi Arabia: Results from a capacity Building, Multi-Stakeholder workshop.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- The comparative assessment of awareness, perspective, and basic practice skills about the Saudi pharmacovigilance system among students of different health-care professionals of a Saudi Female University.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.Bone marrow transplantation · 2020Review
- Public knowledge, perception, and experience with generic medications in Saudi Arabia.Saudi medical journal · 2020Article
- Effects of phenolic acids from ginseng rhizosphere on soil fungi structure, richness and diversity in consecutive monoculturing of ginseng.Saudi journal of biological sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-quality medicines deliver sub-optimal clinical outcomes and waste precious health resources. It is important to ensure that public funds are spent on healthcare technologies that meet national regulatory bodies such as the Saudi Food and Drug Authority (SFDA), quality standards for safety, efficacy, and quality. Medicines quality is a complicated combination of pre-market regulatory specifications, appropriate sourcing of ingredients (active pharmaceutical ingredient (API), excipients, etc.), manufacturing processes, healthcare ecosystem communications, and regular and robust pharmacovigilance practices. A recent conference in Riyadh, sponsored by King Saud University, sought to discuss these issues and develop specific policy recommendations for the Saudi 2030 Vision plan. This and other efforts will require more and more creative educational programs for physicians, pharmacists, hospitals, and patients, and, most importantly evolving regulations on quality standards and oversight by Saudi health authorities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.